Cullinan Oncology
CGEM
183 hedge funds and large institutions have $1.3B invested in Cullinan Oncology in 2026 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 84 increasing their positions, 46 reducing their positions, and 20 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 46
60% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 20
40% more capital invested
Capital invested by funds: $931M → $1.3B (+$373M)
20% more call options, than puts
Call options by funds: $3.38M | Put options by funds: $2.81M
8.21% more ownership
Funds ownership: 108.32% → 116.53% (+8.2%)
5% more funds holding
Funds holding: 174 → 183 (+9)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$30.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$16.7M |
| 4 |
BlackRock
New York
|
+$11.6M |
| 5 |
BCM
Boone Capital Management
Atlanta,
Georgia
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$16.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$14.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.3M |
| 4 |
BOCH
Blue Owl Capital Holdings
New York
|
-$5.49M |
| 5 |
DM
Deerfield Management
New York
|
-$5.49M |
CGEM Hedge Fund Activity: Q2 2026 in Review
183 of the 8,295 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q2 2026, worth a combined $1.3B — up 40% from $931M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CGEM positions and 20 closed out — a net gain of 12 holders — while 84 added to existing stakes and 46 trimmed.
The largest buyer was MPM BioImpact, adding an estimated $30.9M. The largest seller was Nextech Invest, exiting entirely with an estimated $16.2M sold.
- 183 institutional investors held Cullinan Oncology (CGEM) as of Q2 2026, up from 174 in Q1 2026.
- Funds reported $1.3B of Cullinan Oncology stock for Q2 2026, up 40% quarter-over-quarter.
- 32 funds opened new Cullinan Oncology positions in Q2 2026 and 20 closed out, a net change of +12 holders.
- The largest Cullinan Oncology buyer in Q2 2026 was MPM BioImpact, an estimated $30.9M added.
- The largest Cullinan Oncology seller in Q2 2026 was Nextech Invest, an estimated $16.2M sold.
Based on aggregated 13F filings for Q2 2026.